About the Company
impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
70
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMPL News
New report shows sustained growth for Washington's life science industry
The life science industry had a statewide economic impact of $38.8 billion in 2022, up from $35.3 billion in 2021, according ...
Expert Ratings For Apellis Pharmaceuticals
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
No New Safety Signals Seen With Migraine Prevention Drug
DENVER -- No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long ...
Loading the latest forecasts...